December 2019 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Pharma announces confirmation of a 2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine G

("Midatech" or the "Company")

Midatech Pharma announces confirmation

of a 2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma,

a rare and fatal form of childhood brain cancer

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:

MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased

to announce that it has received confirmation of a 2.6 million EU grant to be used to conduct a ground-breaking clinical

study, GlioKIDS, designed to demonstrate the efficacy of MTX110 as a treatment for Diffuse

Intrinsic Pontine Glioma ("DIPG"), a rare and fatal form of childhood brain cancer with

an average life expectancy of 7 to 9 months.

The grant is under the EU EIC Accelerator

SME Instrument and is part of the European Innovation Council ("EIC") that supports top class innovators and small

companies with funding opportunities to establish market-creating innovations that shape new markets and generate jobs, growth

and higher standards of living. According to the EU, there are 6000 applications per year, of which 4 to 5% are selected.

The funds are subject to finalisation of

the grant agreement currently being prepared with the EU, a process which is anticipated to conclude in early 2020, following which

Midatech will look to start the European study, an open label trial of about 20 patients with a one-year treatment period. The

grant covers 70% of the expected study costs, with the remainder covered by Midatech.

GlioKIDS will be the first ever clinical

trial to use a fully implantable Convection Enhanced Delivery ("CED") catheter system to allow chronic treatment of

brain cancer. Based on pre-clinical research, DIPG tumours are exquisitely sensitive to the anti-cancer actions of MTX110, and

CED administration of MTX110 produces concentrations of MTX110 at the tumour site that are more than 100,000 times higher than

can be achieved with current treatments. To date there are no approved therapeutic treatments and hundreds of clinical trials have

failed in this area.

Orphan Drug Status for this ultra-rare

disease was granted for MTX110 in the US this year providing for a potentially more rapid approval process, assistance from regulatory

agencies during drug development and the opportunity for market exclusivity following approval.

Commenting Craig Cook, CEO of Midatech,

said: "Being selected by the EIC is a major validation of the innovation and value of our MTX110 proposition. These childhood

brain tumours are devastating diseases with very limited treatment options and MTX110 has been formulated specifically to overcome

the limitations of existing therapies and administration. We look forward to continuing our development of MTX110 as an effective

therapy with the potential to make a substantial difference for patients based on its efficacy potential, demonstrated safety,

and the ability to exploit novel and alternative routes of administration that provide a direct to tumour' platform

for the broader application of MTX110, for childhood and adult brain cancers."

announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

For more information, please contact:

for Concentrate for Solution for Infusion is a water-soluble form of panobinostat free base, achieved through complexation with

hydroxypropyl- -cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses

directly to the site of the tumor. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor

(pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (FarydakR) is not suitable for

treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. MTX110

takes the known active HDACi panobinostat (which is available in oral form only), and solubilises it into liquid form using Midatech's

MidaSolve technology. This increases available routes of administration for panobinostat and is essential because the drug does

not cross the blood-brain barrier effectively when given orally. MTX110 can therefore be delivered directly to a patient's tumour

via a catheter system (Convection Enhanced Delivery, or "CED"), infused into and around the tumour under pressure, thereby

bypassing the blood-brain barrier. This technique allows for high drug concentrations to be delivered to the tumour while simultaneously

minimising systemic toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in

vitro and in vivo models, and in a key study it was the most effective of 83 anticancer agents tested in several patient DIPG cell

Midatech Pharma PLC (dual listed on LSE

AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving delivery of drugs

in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide

compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment

for life threatening diseases.

The Company has developed three in-house

technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's

technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

By improving biodelivery and biodistribution

of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks,

accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies

allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility

is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com

in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom

and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate

to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding

the potential treatment options for MTX110 and the development of the programme.

be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance

with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs")

and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important

factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements.

These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking

statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may

be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake

any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise